Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Non-Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai Dongfang Hospital, Shanghai, Shanghai Municipality, China
Zhejiang Provincial Cancer, Hangzhou, Zhejiang, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE3

Phoenix, United States · Burbank, United States

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Non-Small Cell Lung Cancer · Small Cell Lung Cancer · Extrapulmonary Small Cell Cancer

Abroad (travel likely)Recruiting

Bethesda, United States

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Orange, United States · Skokie, United States